Mr. Shingyu Bae is the founder and CEO of MDimune Inc., which is developing innovative therapeutics for incurable disease with BioDrone® drug delivery platform. He served as the Vice President of Business Development of Kainos Medicine Inc. Prior to joining Kainos Medicine, he was a co-founder and CFO of Chemizon Inc. from 2006 to 2011, when he managed a successful M&A for going public in 2007. He also had experiences of equity investment, M&A and IPO in venture capital for 7 years. Prior to joining venture capital, he worked as a senior research scientist at Daesang R&D Center from 1989-1997. He received M.S. in biotechnology from KAIST in 1988 and B.S. from Ajou University.
Innovative Therapeutics Development Using BioDrone® Platform Technology
Tuesday, 10 September 2019 at 11:00
Add to Calendar ▼2019-09-10 11:00:002019-09-10 12:00:00Europe/LondonInnovative Therapeutics Development Using BioDrone® Platform TechnologyCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul, KoreaSELECTBIOenquiries@selectbiosciences.com
MDimune Inc. was founded in 2015 to bring hope to many suffering patients by enabling more efficient drug delivery. Our innovative therapeutics platform called the “BioDrone® Technology” leverages the cell-derived vesicles (CDVs) obtained from various human cells to achieve target-specific drug delivery. Using BioDrone® Technology platform, we are striving to move forward the drug development endeavors against diverse challenges in human health.
Exosomes have emerged as one of the most promising therapeutics in the last decade and are actively pursued to address diverse disease areas including cancer and regenerative medicine. Despite their therapeutic potentials, a small quantity of naturally released exosomes and subsequent purification steps have hindered broader application of exosomes. The BioDrone® Technology recently developed by MDimune drastically improved the yield by producing CDVs using a proprietary extrusion method. Using this innovative technology, researchers can also deliver CDVs loaded with drugs to the specific target (e.g., lesion) more efficiently, which mimics a “drone” that has revolutionized the logistics industry. This technique is a new concept of drug delivery platform technology that can significantly reduce the adverse effects as well as maximize the therapeutic efficacy with a small amount of drug. Recently, the research and development of stem cell-based regenerative medicine has continually expanded, and the efficacy of stem cell-derived exosomes has gained broad attraction. We demonstrated the regenerative potentials of BioDroneTM Technology in multiple disease models. CDVs derived from stem cells enhanced the survival of the alveoli in chronic obstructive pulmonary disease (COPD) animal model. CDVs also alleviated the pain and promoted cartilage regeneration in the osteoarthritis (OA) animal model. Furthermore, CDVs have regenerative potential for damaged neurons as demonstrated in vitro in the neurodegenerative disease models such as Alzheimer's disease and Parkinson's disease. Currently, MDimune is striving to expand partnerships with biotech, pharmaceutical companies and hospitals to develop innovative therapies based on BioDrone® Technology.
Add to Calendar ▼2019-09-09 00:00:002019-09-10 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul, KoreaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-09-10 11:00:002019-09-10 12:00:00Europe/LondonInnovative Therapeutics Development Using BioDrone® Platform TechnologyCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul, KoreaSELECTBIOenquiries@selectbiosciences.com
